Long-term treatment durability and safety after switching to bictegravir/emtricitabine/tenofovir alafenamide in real-world practice: a 144-week update from the BICTEL cohort
Long-term treatment durability and safety after switching to bictegravir/emtricitabine/tenofovir alafenamide in real-world practice: a 144-week update from the BICTEL cohort. // International Journal of Antimicrobial Agents. – URL: https://www.sciencedirect.com/science/article/pii/S0924857926002785?dgcid=rss_sd_all
Long-term treatment durability and safety after switching to bictegravir/emtricitabine/tenofovir alafenamide in real-world practice: a 144-week update from the BICTEL cohort. International Journal of Antimicrobial Agents. https://www.sciencedirect.com/science/article/pii/S0924857926002785?dgcid=rss_sd_all
“Long-term treatment durability and safety after switching to bictegravir/emtricitabine/tenofovir alafenamide in real-world practice: a 144-week update from the BICTEL cohort.” International Journal of Antimicrobial Agents.
@article{article49428,
title = {Long-term treatment durability and safety after switching to bictegravir/emtricitabine/tenofovir alafenamide in real-world practice: a 144-week update from the BICTEL cohort},
journal = {International Journal of Antimicrobial Agents},
url = {https://www.sciencedirect.com/science/article/pii/S0924857926002785?dgcid=rss_sd_all}
}